# Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion

> **NCT01827722** · PHASE4 · UNKNOWN · sponsor: **Valley Retina Institute** · enrollment: 45 (estimated)

## Conditions studied

- Macular Edema
- Central Retinal Vein Occlusion

## Interventions

- **DRUG:** Ozurdex
- **DRUG:** Ranibizumab
- **DRUG:** Combination Ozurdex with Ranibizumab PRN

## Key facts

- **NCT ID:** NCT01827722
- **Lead sponsor:** Valley Retina Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2016-05
- **Final completion:** 2016-12
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2015-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01827722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01827722, "Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01827722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*